This page shows the latest macular degeneration news and features for those working in and with pharma, biotech and healthcare.
David Kirn, co-founder and chief executive officer of 4DMT, outlined that over 70 patients have been dosed with R100-based product candidates in wet age-related macular degeneration and rare
age-related macular degeneration – a major cause of moderate and severe loss of central vision in ageing adults.
to age-related macular degeneration (AMD).
older and cheaper alternative drug to treat wet age-related macular degeneration (AMD).
Roche has announced the approval of Vabysmo (faricimab) by the European Commission (EC) for the treatment of neovascular age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema
Cimerli is interchangeable for retinal indications including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularisation.
More from news
Approximately 6 fully matching, plus 131 partially matching documents found.
for advanced dry Age-related Macular Degeneration (AMD).
RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... A phase 2 study in the condition Geographic Atrophy (GA), which is the advanced stage of dry
treatments for age-related macular degeneration (AMD).
to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD).
330. Ocular Therapeutics (US). Regeneron (US). Licence collaboration. Hydrogel sustained release aflibercept (Eylea) for wet macular degeneration.
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
related macular degeneration.
While at Genentech he managed the Lucentis phase III clinical programme through to its first approval in wet age related macular degeneration.
Kaberry studied oncology, pharmacology and neurobiology, with a final year project on macular degeneration.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
From Johnson &Johnson’s immunology treatments to Pfizer’s work on a stem cell-based remedy for age-related macular degeneration, pharma companies are quickly realising biotechnology is the future of
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...